Product
Orlistat
Aliases
Alli, Conventional orlistat 120 mg,, Xenical
Name
Xenical
INN Name
orlistat
FDA Approved
Yes
7 clinical trials
1 organization
7 indications
2 documents
Indication
ObesityIndication
Type 1 HyperlipoproteinemiaIndication
Uric AcidIndication
Type 2 DiabetesIndication
Hyperlipoproteinemia Type IIndication
HypertriglyceridemiaIndication
Polybrominated Biphenyl PoisoningClinical trial
A 26-week, Double-blind, Randomized Study in Participants With Overweight or Obesity Investigating the Added Contribution of Acarbose in EMP16 on Efficacy, Safety and TolerabilityStatus: Active (not recruiting), Estimated PCD: 2023-11-21
Clinical trial
Effectiveness of Semaglutide 2.4 mg vs. Commercially Available Medications for Chronic Weight Management in Participants With Obesity in a Multi-employer Setting in The US - a Pragmatic Clinical StudyStatus: Active (not recruiting), Estimated PCD: 2024-11-12
Clinical trial
Long Term Efficacy and Safety of Orlistat for Type 1 Hyperlipoproteinemia: a Randomized, Double-blind, Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2025-04-15
Clinical trial
Observational Study on Clinical Efficacy and Safety of Orlistat in Reducing Uric Acid in Overweight/Obese Patients With HyperuricemiaStatus: Completed, Estimated PCD: 2023-12-01
Clinical trial
An ObEsity-centric Approach With and Without Anti-obesity Medications ComPared to the Usual-care ApprOach to Management of Patients With Obesity and Type 2 Diabetes in an Employer Setting: A Pragmatic Randomized Controlled TrialStatus: Active (not recruiting), Estimated PCD: 2022-08-15
Clinical trial
Orlistat for the Treatment of Type I HyperlipoproteinemiaStatus: Completed, Estimated PCD: 2018-05-31
Clinical trial
Use of a Weight Loss Aid in a Population Exposed to Polybrominated Biphenyls (PBB)Status: Completed, Estimated PCD: 2022-06-30
Document
DailyMed Label: XenicalOrganization
H2-Pharma LLCDocument
DailyMed Label: ORLISTAT